Ariceum Therapeutics has submitted an application for a Clinical Trial Authorization (CTA) in the UK to conduct initial trials of its novel Iodine-123 tagged PARP inhibitor, targeting recurrent glioblastoma patients.
Xeris Biopharma has announced a global licensing agreement with Amgen for a subcutaneous teprotumumab injection using its XeriJect® system for Thyroid Eye Disease.
Verge Genomics has announced the start of its Phase 1b trial for VRG50635, a potential treatment for amyotrophic lateral sclerosis (ALS), covering both sporadic and familial forms.
Constant Therapeutics LLC, specializing in biopharmaceuticals, announced the first patient dosed in their Phase 2 trial of TXA127, a peptide therapy aimed at improving post-stroke recovery.
Fate Therapeutics Reveals Commencement of Initial Human Trial for FT825 / ONO-8250 in Individuals Suffering from HER2-positive Progressive Solid Cancers.
Medison Pharma and Regeneron Ireland DAC have formed an exclusive partnership for Medison to distribute Regeneron's innovative treatment, Libtayo® (cemiplimab).